Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers July 30, 2014
Pharmacy Choice - Pharmacy News - July 30, 2014

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
7/30/14 - AcelRX Selling Off On FDA Reexamination; U.S. FDA Grants Approval for IMBRUVICA®
Below is a look at some of the headlines for companies that made news in the healthcare sector on July 28, 2014.{ nfg} Shares of AcelRx Pharmaceuticals are selling off sharply monday morning after a blow from the FDA to Zalviso. AcelRx made the announcement at an unusual time: 9:59 p.m. ET Friday. The FDA is looking for more information on how to u
7/30/14 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; FDA Safety Communication Readership Survey
SUMMARY: The Food and Drug Administration is announcing that a collection of information entitled " FDA Safety Communication Readership Survey" has been approved by the Office of Management and Budget under the Paperwork Reduction Act of 1995. FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 C
7/30/14 - Blue Belt Technologies Receives 510k Clearance for Patellofemoral Joint Replacement Application
By a News Reporter-Staff News Editor at Biotech Week-- Blue Belt Technologies has received FDA clearance to market their latest surgical application for the Navio ® Surgical System, patellofemoral joint replacement surgery. Smith and Nephew's patellofemoral joint system, Journey PFJ, will be the first implant system available for use with the Navi
7/30/14 - CorMatrix Gets FDA Approval to Market ECM for Vascular Repair [Professional Services Close - Up]
CorMatrix Cardiovascular reported that it has received U.S. Food and Drug Administration clearance to market the CorMatrix ECM for Vascular Repair. Richard F. Neville, Professor of Surgery, Chief, Division of Vascular Surgery at George Washington University said, "CorMatrix ECM for Vascular Repair is an innovative scaffold permitting the patient's
7/30/14 - FDA Confirms Approval of Gilead's Zydelig; FDA Approves Eagle Pharmaceuticals' Ryanodex
FDA said it has approved Gilead Sciences Inc's Zydelig, a drug to treat three types of blood cancer. The FDA approved the use of Zydelig in combination with Roche AG's Rituxan for patients with relapsed chronic lymphocytic leukemia. It also approved Zydelig under a so-called accelerated approval program for relapsed follicular B-cell non-Hodgkin ly
7/30/14 - IMBRUVICA (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p
Release date- 29072014- HORSHAM, PA- The U.S. Food and Drug Administration has approved the supplemental New Drug Application for IMBRUVICA capsules for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. CLL patients with del 17 p are considered to have the poorest prognosis. 2 IMBRUVICA is joi

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Lupus: What You Need to Know
This lesson is supported by:
West Virginia Best Practice Prescribing & Drug Diversion Training
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement